Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew's joint venture with Advanced Tissue Sciences to develop and market Dermagraft bio-engineered skin will be a major driver of S&N growth over the next five years, the British firm anticipates
Advertisement

Related Content

Financings In Brief
Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
Tissue Product Premarket Route, Legal Framework Debated By EU Regulators
AbilityOne To Double Rehabilitation Sales To $200 Mil. With S&N Rehab Unit
EU Tissue Product Approval Should Be Distinct From Devices - EC Cmte.
ATS Dermagraft Approval Breaks Apligraf Monopoly In Chronic Wounds
ATS Dermagraft Approval Breaks Apligraf Monopoly In Chronic Wounds
ATS/Medtronic Expect Epicardial Angiogenesis Device Trials By 2003
Smith & Nephew Expanding Shoulder Repair Offerings Through OBL Purchase
Smith & Nephew
Advertisement
UsernamePublicRestriction

Register

MT017012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel